Immune Therapeutics, Inc. (OTCQB: IMUN) centers its works on
applying its patented immunotherapy to fight chronic diseases, such as cancer,
which affect people of all ages and races all over the world. Leveraging the
body’s natural immune system, the company’s product line and immunotherapy
technologies are engineered to enhance treatment for those suffering with
HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.
One of IMUN’s promising treatments is Low Dose Naltrexone
(LDN), or Lodonal, as it is known on a global scale. Lodonal has its origins in
the FDA-approved 50mg Naltrexone. Initially known to treat opiate dependencies,
the Immune Therapeutics patented treatment, which covers a wide range of
indications, is currently used as an immune modulator. Lodonal /LDN works by
boosting levels of endorphins (peptides produced in the brain and adrenal
glands). These natural peptides are very effective modulators of the immune
system. When patients take Lodonal, it attaches to opioid receptors in the
brain and immune cells and temporarily blocks endorphins signaling the body in
order to increase endorphin production. The increased endorphin production
facilitates the activity of stem cells, macrophages, natural killer cells, T
and B cells and other immune cells. Lodonal is also effective in preventing
immune system over activity, the core of autoimmune disorders, and reduces the
release of inflammatory and neurotoxic chemicals in the brain.
New York physician Dr. Bernard Bihari, who has studied
immune responses primarily in HIV/AIDs patients, has produced a three-point
mechanistic approach to the use of LDN showing the following three distinct
increases within the immune system. The first increase is within met-enkephalin
(an endorphin produced in large amounts in the adrenal medulla) and endorphin
in the blood stream. The second increase occurs within the number and density
of opiate receptors on the tumor cell membranes, thereby making them more
responsive to the growth-inhibiting effects of the already present levels of
endorphins, which in turn induces apoptosis in the cancer cells. Third,
increases are stimulated within absolute numbers of circulating cytotoxic T
cells (CD8+/TH1) and natural killer cells (“NK cells”), as well as NK cell
activity.
IMUN focuses on the development and commercialization of
therapeutic treatments for cancer, HIV/AIDS, autoimmune diseases, and immune
disorders in the United States. Currently, the company is developing IRT-101,
an active immunotherapy systemic administration of methionine-enkephalin that
works by stimulating a patient’s immune system against infectious diseases,
autoimmune diseases, immune disorders, and tumor cells. The company is
headquartered in Orlando, Florida.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment